Management of a Hemidystonic Patient with Thalamotomy, Campotomy and Cervical Dorsal Root Entry Zone Operation

What's new in surgical treatment for dystonia?

It is now established that pallidal deep brain stimulation (DBS) is effective in the treatment of generalized and segmental primary dystonia, although there is still insufficient evidence to support its benefit in focal and secondary dystonia. Because several studies have demonstrated that pallidal DBS improves quality of life (QoL), reduced QoL and disability that are nonresponsive to medical treatment are probably the main factors guiding the decision to consider surgery. Some studies have indicated that young patients with primary dystonia who have shorter disease duration and less severe dystonia are likely to have the best outcome from DBS. Therefore, surgery should not be delayed when disability and QoL are impaired to the extent that justifies the surgical risk. A case-by-case approach is recommended in patients who have secondary dystonia. The globus pallidus internus is considered the best target for dystonia. There are still not enough data about the effectiveness of thalamic, subthalamic nucleus, and premotor cortex stimulation. Targeting with multiple electrodes and intra-individual comparisons of outcomes may help determine which target would be more beneficial. With regard to the role of lesions, pallidotomy for dystonia is still performed in several countries and can play a role in selected patients. New technologies are already available to improve the stimulation programming for DBS patients and to increase battery longevity. In the near future, it is possible that we will be able to shape stimulation settings according to disease type and symptoms. © 2013 Movement Disorder Society.

Surgery for movement disorders

Movement disorders, such as Parkinson's disease, tremor, and dystonia, are among the most common neurological conditions and affect millions of patients. Although medications are the mainstay of therapy for movement disorders, neurosurgery has played an important role in their management for the past 50 years. Surgery is now a viable and safe option for patients with medically intractable Parkinson's disease, essential tremor, and dystonia. In this article, we provide a review of the history, neurocircuitry, indication, technical aspects, outcomes, complications, and emerging neurosurgical approaches for the treatment of movement disorders.

Spinal and Nucleus Caudalis Dorsal Root Entry Zone Operations for Chronic Pain

Objective:

Dorsal root entry zone (DREZ) operations came into medical practice after the demonstration of increased electrical activity in the dorsal horn of the spinal cord and brainstem in patients with deafferentation of the central nervous system after injury to these areas. The aim of the study was to describe the technique and the effectiveness of spinal DREZ and nucleus caudalis (NC) DREZ operations, which may be the treatments of choice in unique chronic pain conditions that do not respond to medical therapy or any other surgical methods.

Methods:

Fifty-five patients (44 spinal, 11 NC DREZ) underwent 59 (48 spinal, 11 NC DREZ) operations. There were 44 men and 11 women with a mean age of 46.4 years (range, 24–74 yr). The mean follow-up period was 72 months (range, 6 mo–20 yr). Follow-up assessments were performed with clinical examination on the first day and in the sixth and twelfth months postoperatively. Patients' pain scores and Karnofsky Performance Scale scores were also evaluated pre- and postoperatively.

Results:

The initial success rates for spinal and NC DREZotomy procedures were 77 and 72.5%, respectively. In the spinal DREZotomy group, mortality occurred in one patient (2.2%). There were two cases of transient muscle weakness (4.4%) and two of cerebrospinal fluid fistulae (4.4%). In the NC DREZotomy group, mortality occurred in one patient (9%). There were two cases of transient ataxia (18%) and two of transient hemiparesis (18%).

Conclusion:

Spinal and trigeminal NC DREZ operations are effective in the treatment of intractable pain syndromes, especially in traumatic brachial plexus avulsions, segmental pain after spinal cord injury, postherpetic neuralgia, topographically limited cancer pain, and atypical facial pain.